UK based biopharmaceutical company SiSaf closes $4.3 million interim funding round
- Led by Vickers Venture Partners, A2 Interim funding round closes oversubscribed
- Capital will drive pipeline development and manufacturing capability in dermatology, cosmetic skin care and other therapeutic areas.
- SiSaf’s ProSilic® bio-courier technology takes even the most challenging molecules to their target and optimises their efficacy and safety
31 May, London – UK based bio-pharmaceutical company SiSaf closes a $4.3million interim funding round led by Vickers Venture Partners with additional capital injections by Invest NI and Innovation Ulster Limited.
SiSaf is a young, commercial stage company that develops drugs using bio-courier technology, ProSilic®, a novel method of drug delivery that is based on a patented hybrid of porous silicon and liposomes. The company plans to use the investment to accelerate the development of its dermatology pipeline.
SiSaf’s Founder and ProSilic inventor, Dr. Suzanne Saffie-Siebert, Ph.D, said:
“There are many molecules in medical use today that have not reached their full therapeutic potential due to inherent limitations, such as limited efficacy, poor solubility, stability, or side effects. We don’t discover new drugs. Instead, we make existing drugs better, by formulating them with our ProSilic bio-courier technology.”
When describing the technology, Suzanne said, “Silicon has transformed the information technology industry and now it’s about to transform healthcare. Like a mobile phone can house any number of apps, silicon-based ProSilic can enable an unlimited number of medicines to become more effective, stable and easier to administer.”
Vickers Ventures Partners, Vice President, Elkhalil Binebine MD who led the investment said,
“We look for sustainable business models with competitive edge and leaders with strength of character. Platform plays are key to our portfolio risk mitigation when we are investing. SiSaf optimizes this model; their unique technology has so many potential applications it’s astonishing. The data in multiple areas is incredibly compelling and we are convinced they will change the face of drug delivery.”
ProSilic’s benefits were recently showcased at the annual South Beach Symposium in Florida. Mark Nestor MD Ph.D, Dermatologist and Symposium Chair said,
“Our skin protects us from the environment, but this formidable biological barrier significantly limits the topical delivery of drugs. The ProSilic delivery system provides the opportunity to deliver numerous dermatological drugs to where they are needed and release them over time both safely and effectively.”
Hannah Barlow, SiSaf media relations
+44 77938 22089
SiSaf a UK HQ’d, commercial stage bio-pharmaceutical company pioneering bio-courier technology, a novel method of drug delivery offering exceptional safety and versatility. In addition to a rich dermatology pipeline, SiSaf also has subsidiaries in high need / high value markets, such as cosmetic skincare and nutraceuticals.
SiSaf’s unique patented bio-courier technology, ProSilic®, is a fully biodegradable hybrid of porous silicon and liposomes. An extremely wide range of molecules can be formulated with ProSilic for improved stability, solubility, bioavailability, release and route of administration.